


Docket No. 62814-A/JPW/GJG



*Application
for
United States Letters Patent*

To all whom it may concern:

Be it known that, we,

**Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin,
Shana M. Kajiji, Barbara A. Foster, Karen J. Ferrante and Sandra L. Silberman**

have invented certain new and useful improvements in

**STABLE POLYMORPH OF N-(3-ETHYNYLPHENYL)-6, 7-BIS (2-METHOXYETHOXY)-
4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND
PHARMACEUTICAL USES THEREOF**

of which the following is a full, clear and exact description.



Dkt. 1919/62814-A/JPW/GJG/JBC

#23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Timothy Norris et al.
Serial No. : 09/711,272 Group Art Unit: 1624
Filed : November 9, 2000 Examiner: T. McKenzie
For : STABLE POLYMORPH OF N-(3-ETHYNYLPHENYL)-6,
7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE
HYDROCHLORIDE, METHODS OF PRODUCTION, AND
PHARMACEUTICAL USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
September 18, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL AMENDMENT AND
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

A Notice of Allowance was issued in connection with the above-identified application by the U.S. Patent and Trademark Office on June 18, 2003 requiring payment of the issue fee by September 18, 2003. Instead of paying the issue fee, applicants are filing a Request for Continued Examination ("RCE") with this Supplemental Amendment and Supplemental Information Disclosure Statement being the "submission" pursuant to 37 C.F.R. §1.114. Accordingly, the subject application is pending today and this Supplemental Amendment and Supplemental Information Disclosure Statement is being timely filed.

RECEIVED
SEP 24 2003
TECH CENTER 1600/2900